Agenus and Zydus Lifesciences have entered a $141M strategic collaboration to advance their BOT/BAL programs and expand Zydus’ biologics manufacturing in the US. Forward-looking statements in this press release highlight the companies’ botensilimab and balstilimab programs, expected regulatory timelines, and filings. It is crucial to note that these statements are subject to risks and uncertainties that could impact actual results. Agenus urges investors to exercise caution when relying on these forward-looking statements, emphasizing the need for updated information based on the law’s requirements.
Read more from businesswireindia.com
